 
 
 
 
 
PeriOcular and INTravitreal corticosteroids  
for uveitic macular edema (POINT) Trial  
Protocol version 2.[ADDRESS_823956]  
Baltimore, MD [ZIP_CODE]  
 
 
ClinicalTrials.gov identifier: [STUDY_ID_REMOVED]  
     
  
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document distribu tion ‚îÇ 2 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823957] DSMC  
JHSPH IRB Office  
Clinical Centers - 
PPM 4  
 04 Jun 2015  
04 Jun 2015  
08 Jun 2015  
 
1.1 06 Aug 2015  New clinic s:  MUHC, 
MEEI, IOWA, OCB, SCRA  
All clinical centers  
JHSPH IRB  
 
 07 Aug 2015  
  11 Aug 2015 (PPM7)  
24 Aug 2015  
 
1.2 23 Feb 2016  WILL, MAYO  
[LOCATION_006]IO  
CC IRB  
UPMC  
All clinical centers  23 Feb 2016  
24 Feb 2016  
11 Mar 2016  
28 Mar 2016  
07 Apr 2016 (PPM 14)  
  
 
2.0 28 Jun 2016  JHSPH IRB  
Clinical centers  6 July 2016  
6 July 2016 (PPM 18)  
 
2.1  
16 Feb 2017   
JHSPH IRB   
21 Feb 2017  
  Clinical Centers  24 Mar 2017 (PPM 37)  
 
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document revision history ‚îÇ 3 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 Document revision history  
 
19 Dec 2014  
 Throughout  
‚Ä¢ Added (Kenalog¬Æ)  as specification for periocular triamcinolone  acetonide  
‚Ä¢ Added clarification for  intravitreal triamcinolone acetonide: Triesence is to be used at U.S. clinics 
and Triesence is preferred at non -U.S. clinics but Kenalog is allowed  
 
 1.[ADDRESS_823958] udy centers  
‚Ä¢ Deleted clinical centers:   
- [LOCATION_005] Eye Research and Surgery Institute,  Cambridge, MA  
- University of [LOCATION_004]- SD, La Jolla, CA  
  3.1 Type of study  
‚Ä¢ Added second stratification variable:  ‚â• .[ADDRESS_823959]  
 
 3.6 Eligibility criteria  
‚Ä¢ Clarified inclusion criterion 3 by [CONTACT_619704]: Macular edema (ME) defined as the 
presence of central subfield macular thickness greater than the normal range for the OCT 
machine being used, regardless of the presence of cysts, as assessed by [CONTACT_619705]  
‚Ä¢ Deleted:  Evidence of leakage on fluorescein angiography at baseline as assessed by [CONTACT_619705];  
 
 3.7 Randomization  
‚Ä¢ Added second stratification variable:  ‚â• .[ADDRESS_823960]  
  3.8 Data collection  
‚Ä¢ Color fundus (disc) images changed to Color fundus/red reflex images  
‚Ä¢ Deleted:  Slit lamp images  
 
16 Jan  2015 
 3.8 Data collection  
‚Ä¢ Clarified that ophthalmic exam includes slit lamp exam and ophthalmoscopy  
 
[ADDRESS_823961]  
‚Ä¢ Removed ‚Äòinitial‚Äô in the sentence:  The question of how to approach regional treatment of uveitic macular edema is a key question for ophthalmologists treating these patients.  
  
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document revision history ‚îÇ 4 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
  
 2.1 Objective  
‚Ä¢ Removed ‚Äòinitial‚Äô in the following:  To evaluate the relative efficacy of three commonly utilized 
regional corticosteroids for the regional treatment of uveitic macular edema:  periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant.  
 
 3.1 Type of study  
‚Ä¢ Deleted stratification variable   ‚â• .[ADDRESS_823962]   
 
3.6 Eligibility  
‚Ä¢ Added inclusion criterion: Baseline fluorescein angiogram that is gradable for degree of le akage 
in the central subfield  
 
 3.7 Randomization  
‚Ä¢ Deleted stratification variable   ‚â• .[ADDRESS_823963]  
 
3.8 Data collection schedule 
‚Ä¢ ‚ÄúColor fundus/red reflex images‚Äù changed to ‚ÄúFundus reflex images‚Äù  
 
6.2 Statistical methods  
In fourth paragraph  made the following changes to accommodate removal of leakage on 
fluorescein angiography as stratification variable : All analyses will be performed both 
unadjusted, except for the stratification variable, and adjusted for potential confounders.  Effect 
mod ification due to factors such as disease location or uveitis activity, fluorescein leakage in the 
cent ral subfield, systemic disease, gender and race also will be explored when appropriate.  
 
16 Feb 2015  
3.6 Eligibility  
‚Ä¢ Corrected misspelling of gradable  
 6 Apr 2015 
Title page  
‚Ä¢ Medical Safety Officer changed  from Douglas A. Jabs, MD, MBA to Akrit Sodhi, MD, PhD  
‚Ä¢ Added: Study Registry ID: [REMOVED]  
 
1.4 Financial sponsor  
‚Ä¢ Added: Allergan (Irvine CA) is donating Ozurdex for the NEI, [LOCATION_006]IO, and RVEE c linical centers  
 
3.3 Trial schema  
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document revision history ‚îÇ 5 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 ‚Ä¢ In footnote ‚Äú¬ß‚Äù changed timeframe of opening of MERIT enrollment from 6 months to 1 year 
after the initiation of POINT  
 
3.6 Eligibility  
‚Ä¢ Participant -level exclusion criterion 1 (History of infectious uveitis, or of scleritis, keratitis, or 
endophthalmitis in either eye) was split into 2 to clarif y that  it history of  infectious  
endophthalmitis is exclusionary:  
1. History of infectious endophthalmitis or infectious uveitis in either eye;  
2. History of scleritis or keratitis of any type in either eye;  
 
3 Jun 2015  
3.3 Trial schema  
‚Ä¢ In footnote   ‚Äú‚Ä†‚Äù  removed ‚Äúbest corrected visual acuity of 20/40 or worse‚Äù as condition for 
second injection  
 
3.6 Eligibility  
‚Ä¢ Inclusion criterion 4 (an eye level criterion) best corrected visual acuity (BCVA) requirement 
changed from ‚ÄúBCVA of 20/40 to 5/200 ‚Äù to ‚ÄúBCVA worse than 20/32 and 5/200 or better ‚Äù  
 
4.2.2 Second injections of assigned treatment  
‚Ä¢ Deleted ‚ÄúBest corrected visual acuity of 20/40 or better‚Äù as repeat injection criterion  
  
6 Aug 2015  
1.5 Investigators and study centers  
‚Ä¢ Deleted: [LOCATION_007] Retina, Dallas, TX  
‚Ä¢ Added 
‚àí Southeast Clinical Research Associates, Charlotte Eye Ear Nose &Throat Associates, 
Charlotte,  NC 
‚àí [LOCATION_005] Eye and Ear Infirmary/Harvard Medical School, [LOCATION_011], MA  
‚àí McGill University and McGill University Health Center, Montreal, QC, Canada  
‚àí Ophthalmic Consultants of [LOCATION_011], [LOCATION_011], MA  
‚àí University of Iowa Hospi[INVESTIGATOR_84059], Iowa City, IA  
‚àí Vision Research/ROPARD Foundation of Associated Retinal Consultants, P.C., Royal Oak, 
MI 
‚àí UW Medicine Eye Institute, University of Washington, Seattle, WA  
 
4.4.3 Possible side effects and complications of treatment s, Intravitreal dexamethasone  ‚Äì added  
‚Äúelevated intraocular pressure which may require surgery to control ‚Äù under less frequently reported 
events  
 
3.1 Design, type of study ‚Äì updated number of clinical centers to 26  
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document revision history ‚îÇ 6 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
  
23 Feb 2016  
1.5 Investigators and study centers  
‚Ä¢ Deleted  
‚àí Southeast Clinical Research Associates, Charlotte Eye Ear Nose &Throat Associates, 
Charlotte, NC  
‚àí Vision Research/ROPARD Foundation of Associated Retinal Consultants, P.C., Royal Oak, MI 
‚Ä¢ Added:  
‚àí Mid Atlantic Retina, Wills Eye Hospi[INVESTIGATOR_307], Philadelphia, PA   
‚àí Mayo Clinic, [COMPANY_002]ster, MN  
 
3.6 Eligibility  
Added new exclusion criterion #11:  (eye level exclusion) Torn or ruptured posterior lens capsule  
 
4.3 Treatment administration guid elines  
‚Ä¢ Added the word ‚Äúguidelines‚Äù 
‚Ä¢ Added note :  Ophthalmologist administering treatment may follow local of standard care 
guidelines for topi[INVESTIGATOR_619691].   
  28 Jun 2016, version 2.0  
1.4 Financ ial sp onsor  
Clarified that Allergan is donating a limited number of Ozurdex for study patients at U.S. clinical centers  
in special circumstances, e.g. patient‚Äôs insurance denies coverage for Ozurdex rather than for use at non-U.S. clinical centers  
 1.5 Investigators and study centers  
‚Ä¢ Change of Principal Investigator [INVESTIGATOR_619692]  
‚àí University of Pennsylvania  
‚àí University of Southern [LOCATION_004]  
‚àí Washington University  
‚Ä¢ Added new clinical center University of Pi[INVESTIGATOR_45589]  
 3.1 Type of stu dy 
‚Ä¢ Changed number of clinical centers from 26 to 27  
 3.3 Trial schema  
‚Ä¢ Second injection IOP criterion changed from ‚â§21 mm Hg with ‚â§ 2 IOP lowering agents to  
‚â§21 mm Hg with ‚â§ 3 IOP lowering agents  
 3.6 Eligibility  
Inclusion criteria  
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document revision history ‚îÇ 7 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 ‚Ä¢ [ADDRESS_823964] machines  
‚Ä¢ [ADDRESS_823965] corrected visual BCVA (i.e., worse than 20/32)  
‚Ä¢ 5 ‚Äì Increased th e number of IOP lowering medications permitted from 2 t o 3 and added 
clarification  that combination medications, i.e.,Cosopt, count as 2 IOP lowering medications  
Exclusion criteria  
‚Ä¢ 3 - New patient -level exclusion  added: History of central serous retinopath y in either eye  
‚Ä¢ 6 ‚Äì Clarification added as italicized for exclusion for oral prednisone dose ‚â§ [ADDRESS_823966] 4 weeks (Note  if patient is off of oral prednisone at 
baseline (P01 visit), dose stability requirement for past 4 weeks does not apply);  
‚Ä¢ Deleted exclusion criterion:  Topi[INVESTIGATOR_619693] 4 weeks.  
 
4.1 Treatment overview  4.2  Treatment schedule  
‚Ä¢ Pre-injection IOP criterion changed from ‚â§21 mm Hg with ‚â§ 2 IOP lowering agents to  
‚â§21 mm Hg with ‚â§ 3 IOP lowering agents  
 
8.  Study timetable  
‚Ä¢ Removed this section because it is out of date.  
 
16 Feb 2017, version 2.1  
1.5 ‚ÄúInvestigators and study centers ‚Äù changed to ‚ÄúResource and clinical centers‚Äù  
‚Ä¢ Replaced list of clinical centers and investigators with note that Clinical Centers and Clinic Directors are listed in the POINT Manual of Procedures in keepi[INVESTIGATOR_619694] n that 
clinical centers are not listed in the protocol for multicenter trials with more than 3 clinical centers .   
 3.3 Trial schema  
‚Ä¢ Clarified that non- responders are eyes demonstrating less than a 20% reduction or worsening of 
ME as measured by [CONTACT_619706]  
‚Ä¢ For dexamethasone arm, added that non -responders could be enrolled in MERIT at P06, if 
eligible  
‚Ä¢ Clarified that second injection time points on schema are the earliest time points for second injection but that second injections can be done at later time points  
‚Ä¢ Revised pre-injection IOP criteria for second injections ‚Äì changed from ‚â§21 mm Hg to <25 mm 
Hg 
‚Ä¢ Updated last sentence in footnote explaining purpose of MERIT Trial regarding treatment of uveitic macular edema persistent after intravitreal corticosteroids; originally MERIT was to focus 
on uveitic macular edema persistent after intravitreal triamcinolo ne acetonide.    
 
3.6  Eligibility criteria  
Exclusion criteria  
‚Ä¢ Patient level exclusion criterion #2 changed  
   From 
2.  History of scleritis or keratitis of any type in either eye  
              To 
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Document revision history ‚îÇ 8 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 2. History of infectious scleritis of any type in either eye . (Note: History of 
noninfectious scleritis that has been active in past 12 months is an eye -level 
exclusion ‚Äìsee #11 below.)  
3. History of keratitis (with the exception of keratitis due to dry eye)in either eye;  
‚Ä¢ Eye level exclusion criterion added 
11. History of active noninfectious scleritis in past 12 months (Note : History of 
noninfectious scleritis is acceptable if the last epi[INVESTIGATOR_15380] 12 months prior to enrollment);  
 
4.1. Treatment  overview  
‚Ä¢ Added to first bullet :  Treatment administration instructions and pre -injection IOP criteria are 
included in sections 4.2 and 4.3.  
‚Ä¢ Added bullet : Treatment according to the best medical judgment of treating study 
ophthalmologist is permitted as deemed necessary. Repeat injections given before the protocol 
specified time points  or other deviations from the treatment protocol  (section 3.3.) should be 
reported expeditiously to CC on Unanticipated Event (UA) form , usually within a few days .   
‚Ä¢ Deleted last bullet:   All injections of study treatments must be administered per protocol 
instructions and follow IOP injection criteria (IOP of ‚â§21 or mm Hg and treatment with ‚â§ 3 IOP -
lowering agents).  
4.2.1 . Initial injections of assigned treatment  
‚Ä¢ Added explicit statement that IOP requirements  for initial injection must be met on day injection 
administered .  
‚Ä¢ Added: Note that  IOP requirements for the initial injection are the same as for eye eligibility for 
the trial. If study treatment is initiated on the same day as eligibility is confirmed and treatment 
assigned, no additional IOP measurements are needed. If circumstances require patient to return to clinic for injection at a later date, IOP must be checked and IOP -lowering agents evaluated 
prior to injection. If the eligibility requirements a re not met, the injection should not be given. If 
the treating ophthalmologist elects to proceed with assigned treatment per best medical judgment, the deviation from the protocol must be reported to CC on an Unanticipated Event (UA) form; the UA form shou ld be submitted as soon as possible , usually within a few days .      
 
4.2.2. Second injections of assigned treatment  
‚Ä¢ Revised IOP requirements for second injection from ‚Äú ‚â§21 mm Hg and ‚â§3 IOP lowering agents‚Äù to 
‚Äú<25 mm Hg and ‚â§3 IOP lowering agents ‚Äù 
 
4.2.3.  Treatment for non -responders (i.e., <20% reduction or worsening of ME)  
‚Ä¢ Clarified the study definition of non -responder: Eyes that demonstrate less than a 20% 
reduction no improvement or worsening of ME as measured by [CONTACT_619707]  
 7.2.2 Confidentiality  
‚Ä¢ Added:  CC will report serious adverse event data for participants randomized to Ozurdex to Allergan (Irvine, CA).  
 Global:  minor edits in reference to changes above and formatting and spelling corrections  
POINT PROTOCOL VERSI ON 2.1 (1 6 FEB 2017)  Abstract ‚îÇ 9 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823967] frequently used 
treatments specifically for uveitic macular edema but there is a lack of high quality evidence to 
guide choice of drug  (e.g., triamcinolone acetonide, dexamethasone) and route  of 
administration (e.g. periocular, intravitreal).  The question of how to approach regional treatment of uveitic macular edema is a key question for ophthalmologists treating these patients.   The 
Perio cular and I ntravitreal Corticosteroids for Uvei tic Macular Edema (POINT) Trial  is a 
randomized trial designed to compare the relative efficacy  of three regional corticosteroids  
commonly utilized  for the initial regional treatment of uveitic macular edema, periocular 
triamcinolone (Kenalog
¬Æ , Bristol -Myers Squibb Company, Princeton, NJ) , intravitreal  
triamcinolone (Triesence‚Ñ¢, Alcon Pharmaceuticals, Fort W orth, TX) , and the intravitreal  
dexamethasone implant  (Ozurdex¬Æ, Allergan, Irvine CA ).   The design outcome is the percent 
change in central subfield macular thickness on OCT from baseline to the 8 week visit.  Follow -
up through 24 weeks will allow evaluation of the duration of response and the need for additional injections.  Secondary outcomes include resolution of macular edema, IOP elevation, 
visual acuity, complications of treatment, and cos t-effectiveness .  
  
POINT PROTOCOL VERSI ON 1.1 (6 AUG 2015)  Contents ‚îÇ 10 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823968]  ................................................................................................................................ 9  
1. Introduction  ...................................................................................................................12 
1.1. Title 12 
1.2. IND exemption  ......................................................................................................12 
1.3. Sponsor -investigator  .............................................................................................12 
1.4. Financial sponsor  ................................................................................................. 12 
1.5. Resource and clinical centers  ...............................................................................12 
1.6. Background and significance ................................................................................12 
2. Objective and study hypothesis  .....................................................................................17 
2.1. Objective  ..............................................................................................................17 
2.2. Hypothesis  ...........................................................................................................17 
3. Design  ...........................................................................................................................18 
3.1. Type of study  ........................................................................................................18 
3.2. Treatment Arms  ....................................................................................................18 
3.3. Trial schema  .........................................................................................................19 
3.4. Primary outcome  ..................................................................................................20 
3.5. Secondary outcomes  ............................................................................................ 20 
3.6. Eligibility criteria  ....................................................................................................21 
3.7. Randomization  .....................................................................................................22 
3.8. Data collection schedule .......................................................................................23 
4. Study treatment schedule and administration ................................................................24 
4.1. Treatment overview  ..............................................................................................24 
4.2. Treatment schedule  ..............................................................................................24 
4.2.1.  Initial injections of assigned treatment  .........................................................24 
4.2.2.  Second injections of assigned treatment ......................................................24 
4.2.3.  Treatment for non -responders (i.e., <20% reduction or worsening of ME)  ...25 
4.3. Treatment administration guidelines  .....................................................................25 
4.3.1.  Administration of periocular triamcinolone acetonide ...................................25 
[IP_ADDRESS].  Posterior sub- Tenon injection ......................................................................[ADDRESS_823969] preparation for all intravitreal injections  ........................................26 
POINT PROTOCOL VERSI ON 1.1 (6 AUG 2015)  Contents ‚îÇ 11 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 4.3.3.  Administration of intravitreal triamcinolone acetonide (Triesence)  ................26 
4.3.4.  Administration of dexamethasone implant (Ozurdex)  ...................................26 
4.4. Possible side effects and complications of treatments  ..........................................27 
4.4.1.  Periocular triamcinolone acetonide ..............................................................27 
4.4.2.  Intravitreal triamcinolone acetonide  .............................................................28 
4.4.3.  Intravitreal dexamethasone ..........................................................................28 
4.4.4.  Intravitreal injection ......................................................................................28 
5. Adverse event reporting ................................................................................................29 
5.1. Adverse events  .....................................................................................................29 
5.2. Serious adverse events  ........................................................................................29 
6. Sample size and statistical methods  ..............................................................................30 
6.1. Sample size, power and detectable differences  ....................................................30 
6.2. Statistical methods  ...............................................................................................32 
7. Regulatory and ethical issues  ........................................................................................34 
7.1. Recruitment and informed consent procedures  ....................................................34 
7.2. IRB/Protection of human subjects  .........................................................................34 
7.2.1.  Potential risks and procedures to minimize risks to participants  ...................34 
7.2.2.  Confidentiality  ..............................................................................................34 
7.2.3.  Inclusion of children  .....................................................................................35 
7.2.4.  Data and safety monitoring ..........................................................................35 
8. References  ....................................................................................................................36 
 
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Introduction  ‚îÇ 12 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 1. Introduction  
 
1.1. Title 
PeriOcular and INTravitreal corticosteroids  for uveitic macular edema (POINT) Trial  
 
1.2. IND exemption  
IND exempt ion granted by [CONTACT_3955] 8 Sep 2013  
 
1.3. Sponsor -investigator  
Janet T. Holbrook, PHD, MPH, Director Coordinating Center  
Johns Hopkins University Bloomberg School of Public Health 
Baltimore, MD  
  
1.4. Financial sponsor  
U-10 grant , National Eye Institute  
 
Allergan (Irvine CA) is donating a limited number of Ozurdex for  study patients at U.S. clinical 
centers  in special circumstances, e.g., patient‚Äôs insurance denies coverage for Ozurdex. .  
Allergan will have no input into study design, management, data analyses, or interpretation of results.  
 
1.5. Resource and clinical  centers  
 
Resource centers   
Center  Director  
Chairman‚Äôs Office   
Icahn School of Medicine at   Mount Sinai ,[LOCATION_001], NY  Douglas A. Jabs, MD, MBA  
Coordinating Center   
Johns Hopkins Bloomberg School of Public Health,  Baltimore, MD  Janet Holbrook, PhD, MPH  
Reading Center   
University of Wisconsin at Madison, Madison, WI  Michael Altaweel, MD  
  
Clinical Centers  and Clinic Directors are listed in the POINT Manual of Procedures   
 
1.6. Background and significance 
Macular edema (ME) is the most common structural complication and cause of visual 
impairment and legal blindness in patients with uveitis.1-3 In a retrospective study from two 
uveitis referral centers in the Netherlands in the early 1990s, 40% of patients with intermediate 
uveitis, posterior uveitis, or panuveitis had ME, and it was the most common cause of visual 
loss among all patients with uveitis, accounting for 41% of visual impairment.3 In the Multicenter 
Uveitis Steroid Treatment (MUST) Tria l, ME was present in approximately 40% of eyes with 
uveitis with a similar frequency for patients with intermediate uveitis, posterior uveitis, and panuveitis .
4-[ADDRESS_823970] common indication for treatment among patients 
with intermediate uveitis .1, 2, 7-9 Furthermore, despi[INVESTIGATOR_619695] 2.1 (16 FEB  2017)  Introduction  ‚îÇ 13 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823971] recently, intravitreal administration of 
anti-vascular endothelial growth factor (VEGF) inhibitors and methotrexate (MTX).
11, 14-[ADDRESS_823972] is often variable with a 
limited duration.18, 19 Pars plana vitrectomy (PPV) and PPV in combination with intravitreal 
corticosteroids have been investigated as treatment options for inflammatory ME unresponsive to medical therapy; however, the impact of this intervention is not yet clear.
20, [ADDRESS_823973] on visual function underscores the need to identify effective alternative medical therapeutic options. 
 
The pathophysiology of ME associated with uveitis is thought to be a consequence of increased vascular permeability from mediators released by [CONTACT_619708], retina, and retinal pi[INVESTIGATOR_43698] (RPE) cells with subsequent accumulation of fluid into the macula, characteristically distributed in the outer plexiform layer of 
the retina.
[ADDRESS_823974], interfere with the release of inflammatory mediators, and decrease VEGF secretion.
22, 23 Models of experimental 
autoimmune uveoretinitis in rats and studies in humans with uveitis and ME show an increased 
concentration of vascular endothelial growth factor (VEGF) in the aqueous humor.24-27 VEGF is 
suspected to play a role in the loss of vascular integrity in the eye and is known to be induced by [CONTACT_15457], such as interleukin (IL) -[ADDRESS_823975] included the use of regional 
corticosteroid therapy, delivered periocularly, including posterior sub -Tenon‚Äôs (PST) and orbital 
floor injections, or via the intravitreal route.
7, 10, 29-[ADDRESS_823976] commonly used drug is triamcinolone acetonide (TA) even though both methylprednisolone and TA have been used for periocular injections. The estimated pharmacologic effect of a regional corticosteroid injection, whether given by [CONTACT_619709], appears to be approximately [ADDRESS_823977] for ME from a variety of etiologies and were followed for a mean of 12 months, a single injection posed relatively little risk of IOP 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Introduction  ‚îÇ 14 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823978] progression whereas with repeated administration, these side effects 
increased.45 A study from the Johns Hopkins Medical Institution of 126 patients (156 eyes) with 
uveitic ME who received a single periocular injection of corticosteroid reported clinical resolution of ME among 53% and 57% of eyes at 1 month and 3 months respectively. 
46 Of the 83 eyes 
that had resolution of ME at 1 month, 50 (60%) had no recurrence of the ME at [ADDRESS_823979] injection.   Of the 21 
eyes treated with a second periocular injection, 81% and 43% had no ME at one and 3 months , 
respectively , after the second injection.   Overall, a 3- line improvement in visual acuity was 
observed in 52% at one month and in 57% at 3- months.   Side effects attributed to periocular 
corticosteroid injections included IOP rise to >30 mm of Hg in 19% (rate = 0.14/eye- year [EY]), 
newly diagnosed cataract in 10% (rate = 0.13/EY), and ptosis in 14% (rate = 0.09/EY).   
The largest study evaluating intravitreal triamcinolone acetonide  in patients with uveitic ME was 
performed at Moorfields Eye Hospi[INVESTIGATOR_307].
33  This retrospective case series of 65 eyes in 54 patients 
found an improvement in ME and visual acuity in 83% of eyes and a mean 12- letter gain (2.4 
lines) in BCVA with intravitreal triamcinolone acetonide with a mean follow -up of [ADDRESS_823980] was raised IOP with 43% experiencing IOP rise >[ADDRESS_823981] to 
intravitreal triamcinolone acetonide in ME from a variety of causes demonstrated a significantly 
increased frequency of IOP> 30 mm Hg and the more frequent need for antiglaucoma medication among the intravitreal triamcinolone acetonide  group with risk factor for the 
development of elevated IOP including; higher baseline IOP, younger age, and the presence of uveitis.
[ADDRESS_823982] 
development has been reported to range from 15-30% after a single injection48-[ADDRESS_823983] been reported to arise in 
25% and 45% of patients33, 48-50, [ADDRESS_823984] instances, elevated IOP is transient and may be controlled with 
antiglaucoma medications; however, surgical intervention may be required.36, [ADDRESS_823985] 
progression requiring surgery was seen in all phakic patients by [CONTACT_941] f ifth injection.
58  In addition, 
intravitreal triamcinolone acetoni de has been shown to be effective in the management of 
persistent ME despi[INVESTIGATOR_619696] 
85%.16, 52, 59, [ADDRESS_823986] been 
approved by [CONTACT_619710] (FDA) for intraocular use, Triesence‚Ñ¢ (Alcon, 
Fort Worth, [LOCATION_007], [LOCATION_003]) and Trivaris ‚Ñ¢ (Allergan Inc., Irvine, [LOCATION_004], [LOCATION_003] ).  
 
In an effort to avert  the limited duration of action of intravitreal triamcinolone acetonide  and 
exposure to systemic medications, sustained release devices have been developed and approved by [CONTACT_619711], a copolymer containing 
dexamethasone, lactic and glycolic acid, which degrades slowly into carbon dioxide and water 
over a period of 6 months following an office based injection into the vitreous cavity.
61-67  The 
safety and efficacy of a single i ntravitreal injection of two dexamethasone  implant doses (0.7mg 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Introduction  ‚îÇ 15 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 and 0.35mg) has been recently reported from the HURON study, a large, 26 week, phase III, 
prospective, multicenter, masked, sham -controlled randomized clinical trial among 229 patients 
with no ninfectious intermediate or posterior uveitis.68  Patients were randomized 1:1:1 to receive 
either a high dose dexamethasone  (0.7mg) implant, low dose dexamethasone (0.35mg) implant, 
or sham injections.  While both implant doses were shown to be effective in controlling vitreous 
inflammation and in improving visual acuity, the higher dose implant proved to have a longer duration of action without a significant increase in untoward ocular side -effects and is the dose 
currently in clinical use.   Vitreous haze scores of zero were achieved in 47% and 36% of the 
high and low dose implants respectively as compared with 12% among sham treated eyes at 8 
weeks, a benefit which persisted among the high dose group to 26 weeks when compared to 
sham.  At 8 weeks, 43% of treated eyes versus 7% in the sham group had at least a 15 letter 
improvement from baseline BCVA while the proportion of eyes achieving this level was 2- to 6- 
fold greater in the dexamethasone implant groups as compared to the sham group throughout 
the study period.  The central macular thickness as measured by [CONTACT_7349] 
(OCT) was significantly lower at weeks 8 and 26 in both dexamethasone  implant groups 
compared to baseline but not statistically different among the sham group.  While the mean 
reduction in macular thickness from baseline was significantly greater in the dexamethasone 
implant  treated eyes at week 8, this was not sustained at week 26.   The percentage of eyes with 
IOP ‚â•25 mm Hg peaked at 7.1% for the high dose implant, 8.7% for the low dose implant, and 
4.2% for the sham group with the ‚â§ 23% of eyes in the high dose group requiring antiglaucoma 
medication and none requiring surgical intervention.   Likewise, at [ADDRESS_823987] between treatment groups (15% high dose, 12% low dose, 7% sham) with no patient requiring surgery.  
 
Subsequent small, retrospective case series confirm the safety and efficacy of the 
dexamethasone implant in eyes with noninfectious posterior uveitis with an improved 
inflammatory activity, visual acuity and a reduction in mean central retinal thickness; however, the durability of the effect may be shorter (3- 4 months) in clinical practice than that reported in 
the HURON trial and require repeated injections.
69-[ADDRESS_823988] measure somewhat different aspects of macular edema, vascular 
leakage and retinal thickness, respectively.  Although the two methods correlate, the correlation 
is moderate, as compensated leakage may not result in thickening, and thickening may occur 
without  evident leakage.
4  Of the three methods (OCT, fluorescein angiography, clinical 
examination), clinical examination is least likely to detect macular edema.4  Visual acuity loss 
correlates better with retinal thickness than with the two- dimensional area of  leakage.73  Even  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Introduction  ‚îÇ 16 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823989] as a 
comparative measure may be adequate to evaluate relative efficacy.  Somewhat longer -term 
follow -up (e.g. 6 months) will be needed to evaluate the duration of response and the need for 
additional injections.  The POINT Trial was designed to compare  the relative efficacy of 
periocular triamcinolone, intravitreal triamcinolone, and intravitreal  dexamethasone as the initial  
regional approach to treatment of macular edema using central  subfield  macular thickness on 
OCT as the primary outcome measure with assess ment of the relative efficacy  at 8 weeks  and 
evaluation of the duration of response and the need for additional injections over 24 weeks of follow -up.   
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Objective and study hypothesis  ‚îÇ 17 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
  
2. Objective and study hypothesis  
 
2.1. Objective 
To evaluate the relative efficacy of three commonly utilized regional corticosteroids for  the 
regional treatment of uveitic macular edema:  periocular triamcinolone acetonide; intravitreal  
triamcinolone acetonide; intravitreal dexamethasone implant.   The primary efficacy measure will 
be percent change in central subfield thickness as measured by [CONTACT_214627] 8 weeks. Participants 
will continue in the study for 24 weeks in order to evaluate relative effects of the 3 treatm ent 
strategies on the duration of treatment effects, requirement for additional  injections, and adverse 
effects.  
 
 
2.2. Hypothesis 
  Primary hypotheses:  
(1) Intravitreal triamcinolone injections will have greater efficacy than periocular 
triamcinolone as a treatment for uveitic macular edema. 
(2) Intravitreal injections of the dexamethasone pellet  will have greater efficacy than 
periocular triamcinolone injections as a treatment for uveitic macular edema. 
(3) Intravitreal injections of the dexamethasone pellet will be non-inferior to intravitreal 
triamcinolone as a treatment for uveitic macular edema. 
  Secondary hypothesis:  
(1) Intravitreal injections of the dexamethasone pellet will have a lower rate of IOP elevation 
than intravitreal triamcinolone injections  over the 24 weeks of follow -up. 
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Design  ‚îÇ 18 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 3. Design 
 
3.1. Type of study  
‚Ä¢ Three- armed, parallel design randomized comparative trial 
‚Ä¢ Allocation ratio 1:1:1  
‚Ä¢ Randomization stratified by [CONTACT_619712] (e.g., oral corticosteroids and/or immunosuppressive drugs) 
‚Ä¢ Unit of randomization is patient, not eye; if both eyes  meet eligibility criteria, both receive 
the assigned  treatment  
‚Ä¢ Multicenter  
‚Ä¢ Fixed sample size, 267 ( 89 per treatment group)  
‚Ä¢ Anniversary close- out at t he 24 week  clinic visit   
‚Ä¢ Reading center graders  assessing primary outcome and visual acuity examiners  masked 
to treatment  
‚Ä¢ Open- label; treating physicians and patients  unmasked to treatment (the therapi[INVESTIGATOR_619697])  
  
3.2. Treatment Arms 
‚Ä¢ Periocular triamcinolone acetonide (Kenalog) (40 mg)  
‚Ä¢ Intravitreal triamcinolone acetonide (preservative- free preparation,  Triescence at U.S. 
clinics; Triesence preferred at non- U.S. clinics but Kenalog allowed) (4 mg)  
‚Ä¢ Dexamethas one intravitreal implant  (Ozurdex)  (0.7 mg)  
 
  
POINT PROTOCOL VERSION 2.1 (16 FEB 2017) Design ‡µü 19 
P:\Doc\MUST\POINT\protocol\17 02 16_2.1\17 02 16 POINT protocol 2 1.docx  
  7ULDOVFKHPD

(\HVPHHWLQJWULDOHOLJLELOLW\FULWHULDUHFHLYHLQLWLDOLQM HFWLRQRIDVVLJQHGWUHDWPHQWDW3YLVLW
¬Ç6HFRQGLQMHFWLRQRIDVVLJQHGWUHDWPHQWSHUPLWWHGDWZHHNYLVL WRUODWHUIRUSHULRFXODUDQG
LQWUDYLWUHDOWULDPFLQRORQHDFHWRQLGHDQGDWZHHNYLVLWRUOD WHUIRULQWUDYLWUHDOGH[DPHWKDVRQH
ZKHQIROORZLQJFRQGLWLRQVDUHPHW 
¬á(\HGRHVQRWPHHWWKHLPSURYHPHQWGHILQLWLRQDGHFUHDVHLQ FHQWUDOVXEILHOG
WKLFNQHVVRIWKHPDFXOD25H\HKDVDQRUPDOFHQWUDOVXEILHOGW KLFNQHVVEXWKDVF\VWRLG
VSDFHVLQWKHPPFHQWUDOVXEILHOG250(LVZRUVHDIWHULQLWL DOLPSURYHPHQW
¬á,23RIPP+JDQGWUHDWPHQWZLWK¬î,23ORZHULQJDJHQWV
√Å(\HVGHPRQVWUDWLQJUHGXFWLRQRUZRUVHQLQJRI0(DVPHDVX UHGE\WKHFHQWUDOVXEILHOG
PDFXODUWKLFNQHVVRQ2&7DUHFRQVLGHUHGSULPDU\WUHDWPHQWQRQU HVSRQGHUVDWWKHVHWLPHSRLQWV
¬Ü0DFXODU(GHPD5DQLEL]XPDEY,QWUDYLWUHDO$QWLLQIOD[COMPANY_003]WRU\7 KHUDS\0(5,77ULDOLVD
FRPSDQLRQVWXG\WR32,17IXQGHGE\WKHVDPHJUDQWIRUWUHDWPH QWRIPDFXODUHGHPDSHUVLVWLQJ
DIWHULQWUDYLWUHDOWULDPFLQRORQHWKHUDS\0(5,7ZLOOEHJLQHQU ROOPHQWDSSUR[LPDWHO\\HDUDIWHUWKH
LQLWLDWLRQRI32,17DQGFRQWLQXHFRQFXUUHQWO\32,17SDUWLFLSDQ WVZKRPHHW0(5,7HOLJLELOLW\
FULWHULDDWLQGLFDWHGWLPHSRLQWVPD\HQUROOLQ0(5,7ZKLOHFRQ FXUUHQWO\FRPSOHWLQJIROORZXSLQ
32,170(5,7ZLOOHYDOXDWHWKHUHODWLYHHIIHFWLYHQHVVDPRQJWZ RUHJLRQDOO\DGPLQLVWHUHG
DOWHUQDWLYHVWRUHJLRQDOFRUWLFRVWHURLGLQMHFWLRQVDLQWUDYLW UHDOUDQLEL]XPDE/XFHQWLV¬ä*HQHQWHFK
,QF6DQ)UDQFLVFR&$DQGELQWUDYLWUHDOPHWKRWUH[DWH07; ZLWKFWKHLQWUDYLWUHDO
GH[DPHWKDVRQH2]XUGH[IRUWKHWUHDWPHQWRIXYHLWLFPDFXODUHG HPDSHUVLVWHQWDIWHULQWUDYLWUHDO
FRUWLFRVWHURLGV

3
 9LVLW,'
:HHN
3HULRFXODUWULDPFLQRORQHDFHWRQLGHPJ 
,QLWLDOLQMHFWLRQ
  QGLQMHFWLRQ
 SHUPLWWHG¬Ç
3
 3
 3
 3
,QWUDYLWUHDOWULDPFLQRORQHDFHWRQLGHPJ 
,QLWLDOLQMHFWLRQ
 QGLQMHFWLRQ
 SHUPLWWHG¬Ç

'H[DPHWKDVRQHLQWUDYLWUHDOLPSODQWPJ

 
 
 
 
'H[DPHWKDVRQH
 LQWUDYLWUHDO LPSODQW
PJ
,QLWLDOLQMHFWLRQ
    QGLQMHFWLRQSHUPLWWHG
1RQUHVSRQGHUV√Åƒ∫0(5,7RU%0-
1RQUHVSRQGHUV√Åƒ∫0(5,7¬ÜRU%0-,PSURYHPHQWFULWHULDQRW
  PHWLQILUVWZHHNV  ƒ∫0(5,7
¬ÜRU%0-
1RQUHVSRQGHUV√Åƒ∫,97$ ,I,97$DWZN	
,I,23FULWHULDPHWLPS URYHPHQWFULWHULDQRWPHW
ƒ∫0(5,7¬ÜRU%0-


3
$OOVXEMHFWVIROORZHGWKURXJKZHHN 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Design  ‚îÇ 20 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823990] outcomes will be performed by  [CONTACT_15467].  
 
3.5. Secondary outcomes  
‚Ä¢ Rate of IOP elevation of >21 mm Hg or ‚â• 10 mm Hg from baseline during the 24 weeks 
of follow -up  
‚Ä¢ Percent change in macular thickness as measured by [CONTACT_15468] 24 weeks of follow -
up 
‚Ä¢ Proportion of eyes with macular edema events  over the 24 weeks of follow -up 
- ‚â•20% reduction in macular thickness (or normalization of macular thickness even 
if there is <20% reduction)   
- ‚ÄùResolution‚Äù, defined as normalization of the macular thickness  to within  +[ADDRESS_823991] machine used  
- Worsening defined as a 20% increase in macular thickness from the lowest value 
after an injection 
- ‚ÄúRecurrence‚Äù defined as >20% increase in the central subfield measurement on 
OCT to an abnormal value in an eye that previously had resolution of ME  
‚Ä¢ Mean change in BCVA over the [ADDRESS_823992]-corrected visual acuity score will be measured at every study visit under 
standardized lighting conditions by [CONTACT_15469] (ETDRS) visual acuity charts,  according to the method described by 
[CONTACT_15470], et al .75 
‚Ä¢ Inflammation as graded using the semi quantitative scales used in the MUST Trial  i.e., 
clinician grading of the presence and extent of  anterior chamber cells, anterior vitr eous 
cells, and vitreous haze based on previously publis hed standard ordinal scales (0, trace, 
1+, 2+, 3+, 4+)76-78 using the scales endorsed by [CONTACT_619713]79 
‚Ä¢ Safety outcomes  including elevated IOP ( >30 mm Hg thresholds  ); new onset  posterior  
subcaps ular (PSC)  cataract  or progression of pre-existing  PSC (using  the Age-Related  
Eye Disease  Study  [AREDS]  scheme80; vitreo us hemorrhage; retinal  tear/detachment ; 
endopht halmitis ; severe vision loss (‚â•15 Early  Treatment  Diabetic  Retin opathy  Study  
[ETDRS] letters) during the 24 weeks of follow -up. 
‚Ä¢ Cost-effectiveness  of treatment s for uveitic macular edema during the 24 weeks of 
follow -up will be assessed by [CONTACT_619714] 24 week follow -up; participants‚Äô  utilities  will be measure with the EuroQ ol 
questionnaire.  
‚Ä¢ Visual function related quality of life as measured by [CONTACT_619715] (25 item version).  
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Design  ‚îÇ 21 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 3.6. Eligibility criteria  
Inclusion criteria:  
      Patient level inclusion criterion:  
 
1. 18 years of age or older;  
 
       Eye level inclusion criteria - at least one eye must meet all of the following conditions  
 
2. Non-infectious anterior, intermediate, posterior or panuveitis; either active or inactive 
uveitis is acceptable;  
 
3. Macular edema (ME) defined as the presence of central subfield macular thickness 
greater than the normal range for the OCT machine being used  (>300 Œºm for Zeiss 
Cirrus/Topcon 3DOCT or >320 Œºm for Heidelberg Spectralis) , regardless of the 
presence of cysts, as assessed by [CONTACT_619705];  
 
 
4. Best corrected visual acuity (BCVA)  5/200 or better ;  
 
 
5. Baseline intraocular pressure > 5 mm Hg and ‚â§ 21 mm Hg (current use of 3 or fewer 
intraocular pressure- lowering medications and/or prior glaucoma surgery are 
acceptable ‚Äì note that combination medications, i.e., Cosopt, count as 2 IOP 
lowering medications ); 
 
6. Baseline f luorescein angiogram that is gradable for degree of leakage in the central 
subfield  
 
7. Pupi[INVESTIGATOR_619698].  
 
Exclusion criteria:  
      Patient level exclusion criteria:  
1. History of infectious endophthalmitis or infectious uveitis in either eye;  
 
2. History of infectious scleritis of any type in either eye. (Note:  History of noninfectious 
scleritis that has been active in past 12 months is an eye-level exclusion ‚Äìsee #11 
below.)  
 3. History of  keratitis (with the exception of keratitis due to dry eye) in either eye;  
 
4. History of central serous retinopathy in either eye;  
 
5. For women of childbearing potential: pregnancy, breastfeeding, or a positive 
pregnancy test; unwilling to practice an  adequate birth control method (abstinence, 
combination barrier and spermicide, or hormonal)  for duration of trial ;  
 
6. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;  
 
7. Oral prednisone  dose > 10 mg per day (or of an alternative corticosteroid at a dose 
higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ‚â§ 
[ADDRESS_823993] 4 weeks  (note that  if 
patient is off of oral prednisone at baseline (P01 vi sit), dose stability requirement for 
past 4 weeks does not apply) ;   
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Design  ‚îÇ 22 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_823994] 4 
weeks;  
 
9. Known allergy or hypersensitivity to any component of the study drugs;  
 
Eye level exclusion criteria - at least one eye that meets all inclusion criteria cannot have 
any of the following conditions:  
 
10. History of  severe glaucoma as defined  by [CONTACT_15443] (cup/disc ratio of ‚â• 0.9 or any notching of optic nerve to the ri m); 
 
11.  History of active n oninfectious  scleritis i n past 12 months (Note : History of 
noninfectious scleritis is acceptable if the last epi[INVESTIGATOR_15380] 12 months prior to enrollment) ; 
 
12. Media opacity causing inability to assess fundus or perform OCT;  
 
13. Presence of an epi[INVESTIGATOR_619699] (i.e., 
causing substantial wrinkling of the retinal surface)81; 
 
14. Torn or ruptured posterior lens capsule 
 
15. Presence of silicone oil; 
 
16. Periocular or intravitreal corticosteroid injection in past 8 weeks;  
 
17. Injection of dexamethasone intravitreal implant in past 12 weeks;  
 
18. Placement of  fluocinolone acetonide implant (Retisert) in past 3 years;  
 
 
 
3.7. Randomization  
After the patient has given written informed consent, eligibility has been confirmed and baseline 
data have been keyed and passed an electronic eligibility review, the patient will be randomly 
assigned to one of the three treatment groups, via a web- based system, returning the treatment 
assignment result in real time.  Receipt of treatment assignment will be confirmed by [CONTACT_619716] -
entry of the treatment assignment.  Beginning at this point, the patient‚Äôs  data will be included for 
primary analyses, regardless of subsequent actual treatment and/or extent of adherence to 
therapy. Randomization will be accomplished using an auditable, documented scheme generating a reproducible order of assignment. Randomization schedules will be developed by 
[CONTACT_5081] (CC), using permuted blocks of varying lengths, designed to yield 
expected assignment ratio of 1:1:1. Randomization will be stratified by [CONTACT_619717] (e.g., oral corticosteroids and/or immunosuppressive 
drugs).   
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Design  ‚îÇ 23 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 3.8. Data collection schedule  
Visit ID P01 P02 P03 P04 P05 P06 
Time Baseline  4-wk 8-wk 12-wk 20-wk 24-wk 
Medical/ophthalmic history  X X X X X X 
Treatment history  X X X X X X 
Best-corrected visual acuity  X X X X X X 
Tonometry  X X X X X X 
Ophthalmic exam  (slit lamp 
exam and oph thalmo scopy)  X X X X X X 
Gonioscopy  X      
OCT  X X X X X X 
Fundus  reflex  images  X     X 
Fluorescein angiogram  X      
EuroQol Questionnaire  X X X X X X 
Visual Functioning 
Questionnaire - 25 X X X X X X 
Adverse event monitoring  X X X X X X 
Pregnancy testing‚Ä† X      
‚Ä†   Required for women of childbearing potential   
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Study treatment schedule and administration  ‚îÇ 24 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 4. Study treatment  schedule and administration  
 
 
4.1. Treatment overview  
‚Ä¢ The timing and administration of initial injections and earliest permissible second injections of assigned treatment are specified by [CONTACT_760].  Treatment administration 
instructions and pre- injection  IOP criteria are included in sections 4.2 and 4.3. 
‚Ä¢ Additional guidance is provided for treatment of non- responders and simultaneous 
enrollment  of eligible patients in the  MERIT Trial at certain  time points .  
‚Ä¢ The protocol  does not prescribe treatment options for every situation  
‚Ä¢ Treatment according to the best medical judgment of treating study ophthalmologist is  
permitted as deemed necessary.  Repeat injections given before the protocol specified 
time points  (section 3.3.) or other deviations from the treatment protocol should be 
reported expeditiously to CC on Unanticipated Event (UA) form, usually within a few days.    
  
4.2. Treatment schedule  
 
4.2.1. Initial injections of assigned treatment  
‚Ä¢ Patients will be randomized to receive an injection of one of three treatments; doses and 
routes of administration are those standardly used in clinical care:   
- Triamcinolone acetonide 40 mg given by [CONTACT_619718]  
- Triamcinolone acetonide 4 mg given by [CONTACT_619719]  
- Intravitreal placement injection of  the 0.7 mg dexamethasone implant  
‚Ä¢ Injection of assigned treatment should be given on the day of randomization or as soon 
after randomization as possible 
‚Ä¢ IOP requir ements for injec tion of initial study treatment must be met on the day the 
treatment is administered : 
-   ‚â§21 or mm Hg and treatment  
-  ‚â§ 3 IOP -lowering agents  (combination meds, e.g., Cosopt, count as 2 agents)  
 
Note that the IOP requirements for the initial injection are the same as for eye eligibility 
for the trial. If study treatment is initiated on the same day as eligibility is confirmed and 
treatment assigned, no additional IOP measurements are needed. If circumstances 
require patient to return to clinic for injection at a later date, IOP must be checked and 
IOP-lowering agents evaluated prior to  injection.  If the eligibility requirements are not 
met, the injection should not be given.  If the treating ophthalmologist elects to proceed 
with assigned treatment per best medical judgment, the deviation from the protocol 
must be reported to CC on an Unanticipated Event (UA) form ; the UA form should be 
submitted as soon as possible usually within a few days .      
   
4.2.2. Second injections of assigned treatment  
Second injections of assigned treatment are  permitted at or after  specified time points if  
macular edema has not improved and re- treatment  criteria  are met .  The  time points  and IOP 
limitations for second inject ions of periocular triamcinolone and intravitreal triamcinolone are 
consistent with typi[INVESTIGATOR_619700].  
‚Ä¢ Time point s for second  injection : 
- Periocular triamcinolone acetonide :  [ADDRESS_823995]  (i.e., after 
ascertainment of primary outcome data)  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Study treatment schedule and administration  ‚îÇ 25 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 - Intravitreal triamcinolone acetonide: [ADDRESS_823996]   
- Intravitreal dexamethasone: [ADDRESS_823997]  
 
‚Ä¢ Reasons to give second injection: 
- Eye does not meet the improvement definition (a 20% decrease in central 
subfield thickness of the macula)  
- ME is worse after initial improvement  
- Eye has a normal central subfield thickness but has cystoid spaces in the 1 mm 
central subfield 
 
‚Ä¢ Re-treatment  IOP requirements : 
- <25  mm Hg    
- ‚â§ 3 IOP-lowering agents  (combination meds, e.g., Cosopt, count as 2 agents ) 
 
4.2.3. Treatment for non- responders (i.e., <20% reduction or worsening of ME)   
Eyes that demonstrate  less than a 20% reduction  or worsening of ME as measured  by [CONTACT_619720] O CT at time points specified below will be cons idered primary  
treatment failures and will be handled in the following manner:  
 
‚Ä¢ Eyes in periocular triamcinolone arm at 12 weeks   
- Intravitreal triamcinolone acetonide 4mg if following conditions met:   
ÔÇß IOP of  <25 mm Hg and treatment with ‚â§3 IOP-lowering agents  
- Follow to close- out visit (week 24)  
 
‚Ä¢ Eyes in intravitreal triamcinolone acetonide arm at [ADDRESS_823998] medical 
judgment  
- Follow to close -out visit (week 24)  
 
‚Ä¢ Eyes in the intravitreal dexamethasone arm at [ADDRESS_823999] medical judgment  
- Follow to the close- out visit (week 24)  
 
 
4.3. Treatment administration guidelines  
Note:  Ophthalmologist administering treatment may follow local of standard care guidelines for topi[INVESTIGATOR_619701].   
 
4.3.1. Administration of periocular triamcinolone acetonide  
The injection may be given either by [CONTACT_619721]- Tenon‚Äôs  approach or by [CONTACT_619722], as both appear to have similar efficacy; the approach to the periocular injection will 
be recorded for analysis if needed.  
  
[IP_ADDRESS]. Posterior sub -Tenon injection  
‚Ä¢ Saturate a cotton- tipped applicator with topi[INVESTIGATOR_15413]  (e.g., in 1 or 2% lidocaine) and 
place under the upper lid for posterior sub -Tenon‚Äôs approach   
‚Ä¢ Instruct patient to look inferonasally  with eye to receive injection 
‚Ä¢ Retract upper lid 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Study treatment schedule and adminis tration  ‚îÇ 26 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 ‚Ä¢ Introduce needle (e.g., 16 -mm 25 gauge needle) into the sub -Tenon space, bevel side 
down  
‚Ä¢ Advance needle with a lateral to and fro motion to ensure the tip does not engage sclera  
‚Ä¢ When needle is judged to be behind the macula, deliver 40- mg (1 -mL) bolus of 
triamcinolone acetonide43 
 
[IP_ADDRESS]. Orbital floor  injection  
‚Ä¢ Saturate a cotton- tipped applicator  with topi[INVESTIGATOR_15413] (e.g.,  1 or 2% lidocaine) and 
place in inferior fornix where needle will be directed 
‚Ä¢ Introduce needle (e.g., 25 -mm 25 gauge) at the lateral third of the inferior orbital rim  
‚Ä¢ Pass needle posteriorly parallel to the orbital floor periosteum to approximately 25 mm 
depth  
‚Ä¢ Slowly deliver 40- mg (1 -mL volume) bolus of triamcinolone acetonide43  
 
 
4.3.2. Standard preparation for all intravitreal injections 
Intravitreal injection procedures should be carried out under controlled aseptic conditions which 
include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate 
anesthesia and a broad- spectrum microbicide such as betadine, applied to the periocular skin, 
eyelid and ocular sur face are required  prior to an intravitreal  injection.  
 
 
4.3.3. Administration of intravitreal triamcinolone acetonide  (Triesence)  
‚Ä¢ Standard preparation as des cribed for intravitreal injections in section 4.3.2.   
‚Ä¢ Saturate a sterile cotton- tipped applicator with 0.5% proparacaine hydrochloride drops 
and hold the swab against the planned intravitreal injection site for [ADDRESS_824000] ival injection of 1% lidocaine hydrochloride ophthalmic 
solution for injection (without epi[INVESTIGATOR_238]).  Alternatively, an injection may be given with 
just topi[INVESTIGATOR_41459].  
‚Ä¢ Use a sterile 4 √ó4 pad in a single wipe to absorb excess liquid and to dry the periocular 
skin. 
‚Ä¢ Instruct subject to direct gaze away from syringe prior to intravitreal injection.  
‚Ä¢ An intravitreal injection using a 30- gauge needle is given [ADDRESS_824001] the patient‚Äôs vision.  
‚Ä¢ Place a cotton swab on the site as the needle is injected to help prevent extrusion of 
medication  
‚Ä¢ Following the intravitreal injection,  patients should be monitored for elevation in IOP  
- Monitoring may consist of a gross assessment of visual acuity  
- Check for perfusion of the optic nerve head immediately after the injection 
and/or tonometry within 30 minutes following the injection  
 
4.3.4. Administration of dexamethasone implant  (Ozurdex)  
‚Ä¢ Standard preparation as described for intravitreal injections in section 4.3.3 above 
‚Ä¢ Saturate a sterile cotton- tipped applicator with 0.5% proparacaine hydrochloride drops 
and hold the swab against the planned intravitreal injection site for 10 seconds in 
preparation for the subconjunctival injection of 1% lidocaine hydrochloride ophthalmic 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Study treatment schedule and administration  ‚îÇ 27 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 solution for injection (without epi[INVESTIGATOR_238]).  Alternatively, an injection may be given with 
just topi[INVESTIGATOR_41459].  
‚Ä¢ Open the foil pouch over a sterile field and gently drop the applicator on a sterile tray  
‚Ä¢ Carefully remove the cap from the applicator  
‚Ä¢ Hold the applicator in one hand and pull the safety tab straight off the applicator ; do not 
twist or flex the tab  
‚Ä¢ Hold long axis of the applicator parallel to the limbus and engage the sclera at an 
oblique angle with the bevel of the needle up (away from the sclera) to create a shelved scleral path  
‚Ä¢ Advance tip of the needle within the sclera for about 1 mm (parallel to the limbus), then 
re-direct  toward the center of the eye and advance until penetration of the sclera is 
completed and the vitreous cavity is entered; do not advance the needle past the point 
where the sleeve touches the conjunctiva.  
‚Ä¢ Slowly depress the actuator  button until an audible click is noted. Before withdrawing the 
applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface.  
‚Ä¢ Remove the needle in the same direction as used to enter the vitreous  
‚Ä¢ Following the intravitreal injection, patients should be monitored for elevation in IO P   
- Monitoring may consist of a gross assessment of visual acuity  
- Check for perfusion of the optic nerve head immediately after the injection 
and/or tonometry within 30 minutes following the injection.
82 
 
 
4.4. Possible side effects and complications of treatments  
 
4.4.1. Periocular triamcinolone acetonide  
Possible side effects and complications associated with periocular triamcinolone acetonide 
injections are similar  to those associated with intravitreal  injectio ns of triamcinolo ne acetonide,  
but rates are  lower  because the drug is not injected directly  into the  eye. 
 
‚Ä¢ Commonly reported  events  
- Elevated intraocular pressure  
- Cataract development  
 
‚Ä¢ Less frequently reported events  
- Ocular discomfort  
- Transient visual blurring 
- Subconjunctival hemorrhage  
- Ptosis  with posterior sub -Tenon‚Äôs injections (risk increases with multiple 
injections)  
 
‚Ä¢ Rare and serious events  
- Glaucoma or severe IOP elevation requiring surgical therapy  
- Breach of sclera  
- Endophthalmitis (occurs with inadvertent breach of sclera and injection of drug into the eye (less than 1 in 1000 cases)  
- Subretinal deposition of drug 
- Retinal tear with or without retinal detachment  
- Vitreous hemorrhage  
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Study treatment schedule and administration  ‚îÇ 28 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
  
4.4.2. Intravitreal triamcinolone acetonide  
‚Ä¢ Commonly reported events (‚â• 20% of patients)  
- Elevated intraocular pressure in up to 40% of cases  
- Cataract development or progression of existing cataract  
- Subconjunctival hemorrhage  
 
‚Ä¢ Less frequently reported events  
- Mild short -term ocular discomfort  
- Short-term visual disturbances  
- Severe increase in eye pressure (~10% of patients), some of whom may require glaucoma surgery
83 
 
‚Ä¢ Rare and serious events  
- Endophthalmitis (infectious and non -infectious)  
- Perforation of the globe where there is thinning of the outer covering of the eye 
- Vitreous hemorrhage  
- Retinal detachment  
- Retinal tear  
 
 
4.4.3. Intravitreal dexamethasone 
‚Ä¢ Commonly reported events  (‚â• 20% of patients)  
- Elevated intraocular pressure which may require medication to lower  
- Subconjunctival hemorrhage  
 
‚Ä¢ Less frequent ly report ed events  
- Mild short -term ocular discomfort  
- Short -term visual disturbances  
- Vitreous detachment  
- Headache 
- Cataract development  
- Elevated intraocular pressure which may require surgery to control  
- In eyes with non- intact posterior capsule implant migration to anterior chamber    
‚Ä¢ Rare  and se rious  events  
- Endophthalm itis 
- Perforation of the globe where there is thinning of the outer covering of the eye 
- Vitreous hemorrhage  
- Retinal detachment  
‚àí Retinal tear  
‚àí  
4.4.4. Intravitreal injection  
Risks of an intravitreal injection that may be associated with the injection procedure itself have 
been included along with each type of drug injection above.  
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Adverse event reporting  ‚îÇ 29 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 5. Adverse event reporting 
5.1. Adverse events   
Adverse events (AEs)  and complications of study treatment  will be record ed on study  data 
forms  and submitted  to the CC.  The CC Safety Officer  and the DSMC Safety Officer  will 
review  all adverse events  and make recommendations to the DSMC  as to any actions  that may 
be needed.  
 
 
5.2. Serious adverse events 
A serious adverse event (SAE) is an adverse event that results in one of the following 
outcomes: death, a life- threatening adverse drug experience, inpatient hospi[INVESTIGATOR_8448], a persistent or significant disability/incapacity, or congenital anomaly/birth defect. Also, important medical events that may not result in death, 
be life -threatening, or require hospi[INVESTIGATOR_3767] a serious adverse event 
when, based upon appropriate medical judgment, they may  jeopardize the patient or subject 
and may require medical or surgical intervention (treatment) to prevent any of the outcomes previously listed in this definition.  
 Clinical centers will report a ll SAEs  to the Coordinating Center expeditiously  regardless  of the 
relationship to study  treatment.  When an investigator or clinical center staff member becomes 
aware of an SAE , it will be reported to the Coordinating Center (CC)  within [ADDRESS_824002]  officer,  the FDA, the pharmaceutical supplier  (where appropriate),  
and all clinical centers in accordance with FDA regulations.  The CC  and clinical centers  will 
submit  all safety  reports  as expedi ted reports  to their IRBs.   Reports  of SAEs not deemed  to be 
unexpected will be submitted to the CC‚Äôs  IRB, to the IRB of the clinical center in which  the 
event was  reported,  as well as to any other  study  center  IRBs  which  require such re ports.  
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Sample size and statistical methods  ‚îÇ 30 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 6. Sample size and statistical methods  
The primary outcome measurement for the POINT Trial is percent change from baseline in 
retinal thickness at 8 weeks.  The primary analysis will be based on the assigned treatment 
and all randomized individuals will be included in the analysis (intention- to-treat) with 
additional sensitivity analyses based on treatment received.  Individuals will be randomized to treatment groups, i.e., all eligible eyes from an individual will receive the same treatment.  
  
6.1. Sample size, power and detectable differences 
The units of analysis for the primary outcome for POINT are eyes as opposed to individuals .  
Since we expect approximately 25% of individuals to have bilateral disease, our sample size 
calculations take advantage of the information from both eyes by [CONTACT_619723], multiple measurements from the same individual.  To arrive at the target sample 
sizes, we first calculated the number of independent eyes needed to power a specific aim (i.e. 
act as though each participant had only one study eye) and then used the following 
adjustment to calculate the required number of individuals:  
 
 NS = NIE * [(1 + r)/ (2*p + (1+r)(1 -p))] 
 
where NS denotes the required number of individuals, N IE denotes the number of independent 
eyes, p denotes the percentage of individuals with bilateral disease (and so two study eyes), 
and r denotes the correlation between eyes86. Estimates for the correlation (r) between 
outcome measurements f or an individual are based upon preliminary data from the MUST 
Trial and FS.  
 
Power calculations for the primary hypotheses are based upon pair -wise comparisons of the 
three treatment arms: intravitreal injection of triamcinolone, dexamethasone pellet, and periocular injection of triamcinolone.  A Bonferroni correction will be used to adjust for multiple comparisons, i.e. a two- sided type I error rate of 0.05/3 = 0.[ZIP_CODE] will be used to determine 
statistical significance.  The sample sizes needed to provide 90% power for the superiority hypotheses (intravitreal injection or dexamethasone pellet versus periocular injection) and 80% 
power for the non- inferiority hypothesis (intravitreal injection versus dexamethasone pellet) were 
computed separately for each comparison and then the maximum sample size was selected.  
The primary outcome is the change in retinal thickness at the central subfield at 8 weeks.  Given 
the skewness in the distribution of retinal thickness, a log- transformation will be used to analyze 
the primary outcome
74, 87; hence, the comparisons will be represented on a relative scale (i.e. 
percent of baseline) and transformed to obtain the percent change from baseline.   A 20% 
change in retinal thickness is associated with clinically meaningful changes in visual acuity.[ADDRESS_824003] Trial, approximately 25% of individuals had bilateral macular edema and the 
correlation between- eyes was 0.[ADDRESS_824004] Trial; a conservative estimate since the treatment of macular edema was not standardized and the timing of the 
assessment, at [ADDRESS_824005] Trial, we allow ed for 
a 10% loss to follow -up. 
For the first two superiority hypotheses, we evaluated the power to show that each of the 
treatment methods for intravitreal corticosteroids (triamcinolone injections and dexamethasone pellets) is superior to periocular triamcinolone injections  at 8 weeks .  In previous studies, 
treatment with the dexamethasone pellet has resulted in a decrease in retinal thickness of 30%-
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Sample size and statistical methods  ‚îÇ 31 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 50%, so a 40% decrease or log change in retinal thickness of log (0.60) = -0.[ADDRESS_824006] a similar level of improvement; whereas periocul ar 
triamcinolone is expected to have a smaller but clinically meaningful change, i.e. a 25% 
reduction or log change of log(0.75) = -0.2877.  Based upon a standard deviation of log- retinal 
thickness of 0.33, a sample size of 89 independent eyes per treatment group, i.e. 89 individuals with one eye for each individual, provides 98% power to detect a 40% reduction in retinal thickness for an intravitreal corticosteroid treatment as compared to a 25% reduction for 
periocular triamcinolone at 8 weeks with a two -sided type I error rate of 0.[ZIP_CODE] (i.e. 0.05/3).  
This number increases to 99 individuals after inflating it for a 10% loss to follow -up.  By [CONTACT_619724] (assuming a between 
eye correlation of 0.4 and 25% bilateral disease), we can reduce our sample size to 89 individuals enrolled in each arm (267 total).  That is, [ADDRESS_824007] hypothes is, we evaluated the power to show that the dexamethasone pellet is non-
inferior to injected triamcinolone. Previous research has indicated that the threshold for reproducibility is 10% and that a 20% change is associated with changes in visual acuity
.74, 88 
Therefore, we chose a non- inferiority margin of 10%, i.e. we would consider the dexamethasone 
pellet to be non -inferior if the percent reduction in retinal thickness was 30% or more (log [0.7]) 
as opposed to a 40% (log [0.60]) in the intravitreal injection group, i.e. the difference in the log 
retinal change was at most 0.15 (log[0.7] ‚Äì log[0.6]) .  A sample size of 89 independent eyes per 
treatment group will provide 80% power to demonstrate non -inferiority with a one -sided type I 
error rate of 0.[ZIP_CODE].  We would reject the null hypothesis of inferiority if the upper bound of the 96.7% confidence interval of the difference in log retinal change from baseline at 8 weeks was 
less than 0.15 (log[0.7] ‚Äì log[0.6]) or equivalently if the ratio of the percent of baseline for the 
two groups was less than 1.16 (0.7/0.6).  Assuming a between- eye correlation of 0.4, 25% 
bilateral disease, and a 10% loss to follow -up, we will need to enroll 89 individuals in each 
treatment arm to attain 80% power, i.e. the inclusion of both eyes for bilateral disease off -sets 
the sample size inflation necessary to account for losses to follow -up. 
An important secondary outcome for the comparison of intravitreal triamcinolone injection versus the dexamethasone pellet will be change in IOP .  In prior studies, treatment with 
intravitreal triamcinolone resulted in IOP elevation for 40% of study eyes.
33, [ADDRESS_824008] been more variable but consistently lower, ranging from 5% to 17%.
62, 68 A sample size of 89 independent eyes per treatment group, which 
is equivalent to 89 individuals per arm allowing for bilateral disease and losses to follow -up, will 
provide 99% power to detect an increase in the percent of eyes with an IOP elevation from 12% 
in the dexamethasone pellet arm to 40% in the intravitreal triamcinolone injection arm with a [ADDRESS_824009] triamcinolone injection 
resulted in clinical improvement for 50 -55% of eyes between one and three months.30, 46 
Intrav itreal triamcinolone and the dexamethasone pellet are expected to result in improvements 
of 35% and 25%, respectively.  Based upon the assumptions outlined above, the sample size of 
[ADDRESS_824010] an increase from 50% to 
85% or 75% with 99.9% or 93% power, respectively, assuming a 2- sided type I error rate of 0.05 
for this important secondary outcome.  
   
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Sample size and statistical methods  ‚îÇ 32 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_824011]. 
Evaluation of continuous outcomes over time (such as log change in retinal thickness or best 
corrected visual acuity) and binary outcomes over time (such as normal/abnormal IOP) will use 
a repeated measures analysis with Gaussian or logit links that account for the nested 
correlations between observations over time and between eyes of the same patient.[ADDRESS_824012] -order, auto- regressive process (an AR(1) model) along with a 
random intercept, will be considered if the unstructured covariance model is unstable.  This 
struc ture allows for correlation to decrease with increasing time- separation down to a level set 
by [CONTACT_464881].  
Significance for superiority hypotheses in POINT will be determined by [CONTACT_17921] p -value of 
the interaction term for the week 8 visit with 0.[ZIP_CODE] (i.e. 0.05/3).  Significance for the non -
inferiority hypothesis in POINT will be assessed by [CONTACT_619725] 96.7% 
confidence intervals for estimate of the difference in change in log retinal thickness  at 8 weeks , 
which is esti mated by [CONTACT_941] 8 -week interaction term, with the defined non-inferiority boundary  of  
0.15 on the log scale, which is equivalent to a 10% difference in percent reduction (40% vs 30% 
reduction) for the two groups.    
Evaluation of risk factors for time-to-event outcomes such as incidence of cataracts, as well as 
time to remission will be performed using Cox proportional hazards regression as well as 
parametric time -to-failure models, such as gamma models
91. Implementatio n of these models 
that allows for clustering (within patients and within eyes), assessment of recurrent events, and 
incorporation of time -dependent covariates  will be used .  When the relevant follow -up time in the 
analysis reflects the clinical time scale (e.g. time since diagnosis of uveitis), it is necessary to 
incorporate the prevalent cases (longstanding diagnosis of uveitis) into the analysis.  To 
accommodate the prevalent cases we will use the staggered entry technique92, which is one 
method of adjusting for potential survival bias.  The analysis compares the event rates among 
patients with similar duration of disease and then combines over these comparisons.  Event 
rates for multiple recurring events, e.g. the number of adverse events, will be modeled using Poisson regression or Negative Binomial regression
93, including a random effects term to 
account for the between eye correlation.   
All analyses will be performed both unadjusted, except for the stratification variable, and 
adjusted for potential confounders.  Effect modification due to factors such as disease location 
or uveitis activity, fluorescein leakage in the centeral subfield, systemic disease, gender and 
race also will be explored when appropriate.  Robust standard errors will be computed using statistical program -based approaches when available and a bootstrap with the individual as the 
sampling unit, when a pre- programmed approach is not available.  
POINT has a focused set of primary research questions and related analyses.  Bonferonni corrections will be applied to control the type I error rates for the primary hypotheses within each 
study.  However, a large number of comparisons are planned for secondary outcomes and 
caution is needed in the reporting of interpretation of the results.  Our primary focus for analyses of these outcomes will be on the parameter estimates and confidence intervals as opposed to p-
values as recommended by [CONTACT_38874]
94. Several methods of adjusting P- values for multiple 
comparisons exist, however no clear consensus as to the most appropriate method is available 
and it is difficult if not impossible to quantify ahead of time the number of comparisons that will 
be performed.  In general, issuing cautions is sufficient, but for identifiable and related sets of 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Sample size and statistical methods  ‚îÇ 33 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_824013], ‚Äòbest‚Äô and ‚Äòworst‚Äô case single imputation techniques will be implement.  In addition,  more sophisticated 
approaches  (e.g. multiple imputation and pattern mixture ) will also be used to assess the impact 
of missing data
95, 96.  For the principal sensitivity analysis, we will retain all features of the 
primary analysis other than how missing values for visits beyond the last one with a measured 
value are handled.  As is implicit in the primary analysis where missing data indicators are used 
(e.g. ‚Äú.‚Äù in SAS, ‚ÄúNA‚Äù in R), we will treat all missing values  as Missing at Random (MAR).  We 
will impute other missing values to generate 10 pseudo- complete records for each such 
individual by [CONTACT_461835] a joint predictive distribution for the missing data given the observed 
data.  We will use a covariance matrix equal to the estimated covariance matrix from the primary 
analysis, but will ‚Äútake control‚Äù of the prediction mean.  Varying the mean of the predictive 
distributio n allows us to assess the sensitivity of our results to a variety of missing data 
scenarios.  The pattern mixture model approach stratifies participants on their pattern of missing data, estimates stratum -specific parameters and then combines estimates over strata using 
inverse variance weights.  The approach is similar to stratified analysis to adjust for potential 
confounders and allows for comparison of stratum -specific estimates.  We stratify by [CONTACT_619726]: complete data, at least one internal measurement missing, and closeout weight missing (along with any other missingness).    
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Regulatory and ethical issues  ‚îÇ 34 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_824014] time to review materials and discuss enrollment with family members when appropriate, the clinic coordinator or study physician will obtain written informed 
consent, using a written, local IRB -approved consent document  based on a prototype prepared 
by [CONTACT_619727]‚Äôs IRB, the JHSPH IRB Office.  The trial is registered on 
www.ClinicalTrials.gov
 ([STUDY_ID_REMOVED]) .  Recruitment efforts and eligibility criteria for POINT are 
subject to review and approval by [CONTACT_619728].  
  
7.2. IRB/Protection of human subjects  
7.2.1. Potential risks and procedures to minimize risks to participants  
The injection procedures, dosage of medication and treatment algorithm within the study will be 
consistent with standard clinical treatment, e.g., sterile technique. To minimize risks associated 
with increased ocular pressure post -injection, patients with uncontrolled ocular hypertension or 
glaucomatous changes will be excluded from the trial.  Patients in the trial will not be exposed to 
risk beyond what they would be exposed to with standard clinical care for their condition.   
Adverse events encountered will be managed by [CONTACT_619729].  
 
7.2.2. Confidentiality  
Confidentiality of patient data will be maintained in accordance with legal regulations.   This 
includes the storage of protected health information (PHI)  in locked cabinets or rooms and 
limited access to secure data areas by [CONTACT_91446] .  Name, social security number, 
address, and other such personal data will be kept solely at the clinical center where the patient receives her/his clinical care.   All transmission of data to the Coordinating Center for analysis is 
done by [CONTACT_619730].  A dataset limited so as to contain a minimal amount of protected 
health information‚Äìthat required to make the data useful for accomplishing the purposes of the 
POINT  Trial‚Äìmay be disclosed, as needed, to collaborating study sites, the NEI, and the FDA.  
Rarely, for reasons of good clinical practice or legal reasons, data with personal information 
may need to be reviewed by [CONTACT_619731], FDA, or DSMB. If such an audit 
occurs, care will be taken to protect confidentiality of participant s. Clinically relevant information 
from the study may be placed in the patient's medical record.  The CC will report s erious 
adverse event data for participants randomized to Ozurdex to Allergan  (Irvine CA ).  Release of 
protected health information to any other persons or organizations will require additional written 
consent of the patient affected, except as required by [CONTACT_2371].  
  A privacy acknowledgment  designed to conform to the specifications of HIPAA regulations  and 
approved by [CONTACT_619732] , will be signed by [CONTACT_619733]/her enrollment  in the study.  
This acknowledgement will be included in the consent form or as a stand- alone document per 
local instit utional requirements.  
  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  Regulatory and ethical issues  ‚îÇ 35 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 7.2.3. Inclusion of children  
Patients  under  18 years  of age will not be included; the intravitreal dexamethasone pellet is not 
approved for use in pediatric patients. 
 
7.2.4. Data and safety monitoring  
Treatment effects  and safety  monitoring will be conducted by a study Data and Safety 
Monitoring Committee (DSMC).   The DSMC will consist mostly of members of the standing 
DSMC , which monitored the Multicenter Uveitis Steroid Treatment (MUST) Trial and now is 
monitoring the MUST Follo w-up Study.  However, the Chair of the MUST DSMC, who is a 
biostatistician, is unable to serve because of potential conflicts of interest.  Hence a new 
biostatistician has been appointed and the Chair of the DSMC for this protocol will be one of the clinic al experts.  The committee consists of voting members  with expertise in biostatistics, 
clinical trial design, ophthalmology, and medical ethics who were appointed by [CONTACT_15496]-
voting members (i.e., Study Officers).  Initially, the DSMC will meet  at least  twice a year, once 
in-person and once by [CONTACT_15498].   For each DSMC meeting,  data will be  summarized in a 
report prepared by [CONTACT_122456].    These reports will include information related to monitoring the 
safety and effectiveness of the study treatments and will include tables and graphs that summarize baseline,  outcome, and adverse event  data by [CONTACT_15500], and if 
indicated, within specific subgroups .  Analyses will be included as  requested by [CONTACT_6802].  
Pertinent information from outside sources such as a reprint of a recent publication reporting on 
results of other, related studies  will also be included as available. The DSMC report will also 
include an overall study performance report, designed for monitoring the effectiveness of the particip ating centers.   
 
The DSMC Safety Officer will be appointed from among the physician voting members of the 
DSMC, who periodically will review summaries of serious adverse event data prepared by [CONTACT_619734] a determination as to whether the event is unexpected 
and possibly related to treatment.    
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 36 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
  
8. References  
Bibliography  
 
1. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11(1):29 -
38. Epub 2003/07/11. PubMed PMID: 12854025.  
2. Lardenoye CW, v an Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. 
Ophthalmology. 2006;113(8):1446- 9. Epub 2006/08/01. doi: 10.1016/j.ophtha.2006.03.027. 
PubMed PMID: 16877081.  
3. Rothova A, Suttorp -van Schulten MS, Frits Treffers W, Kijlstra A. C auses and frequency of 
blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332 -6. 
Epub 1996/04/01. PubMed PMID: 8703885; PubMed Central PMCID: PMC505460.  
4. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The mu lticenter uveitis steroid 
treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 
2010;149(4):550- 61.e10. Epub 2010/01/26. doi: 10.1016/j.ajo.2009.11.019. PubMed PMID: 
20097325; PubMed Central PMCID: PMCPmc2975449.  
5. Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, et al. Fluorescein Angiography versus Optical Coherence Tomography for Diagnosis of Uveitic Macular Edema. Ophthalmology. 
2013. Epub 2013/05/28. doi: 10.1016/j.ophtha.2013.01.069. PubMed PMID: 23706700; Pu bMed 
Central PMCID: PMCPmc3758459.  
6. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, et al. Randomized 
comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916- 26. Epub 2011/08/16. doi: 10.1016/j.ophtha.2011.07.027. 
PubMed PMID: 21840602; PubMed Central PMCID: PMCPmc3191365.  
7. Dong Z, Namba K, Kitaichi N, Goda C, Kitamura M, Ohno S. Efficacy and complications of intravitreal injection of triamcinolone acetonide for refractory cystoid macular edema associated with intraocular inflammation. Jpn J Ophthalmol. 2008;52(5):374 -9. Epub 
2008/11/11. doi: 10.1007/s10384- 008-0574- 2. PubMed PMID:  18991038.  
8. Estafanous MF, Lowder CY, Kaiser PK. Patterns of macular edema in uveitis patients. Ophthalmology. 2005;112(2):360; author reply - 1. Epub 2005/02/05. doi: 
10.1016/j.ophtha.2004.11.011. PubMed PMID: 15691581.  
9. Markomichelakis NN, Halkiadakis  I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, et al. 
Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111(5):946 -53. Epub 2004/05/04. 
doi: 10.1016/j.ophtha.2003.08.037. PubMed PMID: 15121373.  
10. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Archives of ophthalmology. 
2001;119(9):1380- 3. Epub 2001/09/27. PubMed PMID: 11545651.  
11. Ossewaarde -van Norel A, Rothova A. Clinical review: Update on treatment of inflammatory 
macular edema. Ocul Immunol Inflamm. 2011;19(1):75 -83. Epub 2010/11/03. doi: 
10.3109/09273948.2010.509530. PubMed PMID: 21034302.  
12. Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid 
macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145(5):841 -6. Epub 
2008/03/07. doi: 10.1016/j.ajo.2007.12.032 S0002- 9394(08)[ZIP_CODE]- 1 [pii]. PubM ed PMID: 
18321467; PubMed Central PMCID: PMC2574684.  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 37 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 13. Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. 
Ophthalmology. 2010;117(3):585- 90. Epub 2009/12/29. doi: 10.1016/j.ophtha.2009.08.011 
S0161- 6420(09)[ZIP_CODE] -2 [pi i]. PubMed PMID: 20036011; PubMed Central PMCID: PMC2830339.  
14. Hazirolan D, Pleyer U. Think global --act local: intravitreal drug delivery systems in chronic 
noninfectious uveitis. Ophthalmic Res. 2013;49(2):59 -65. Epub 2012/12/22. doi: 
10.1159/000345477 000345477 [pii]. PubMed PMID: 23258374.  
15. Modorati G, Miserocchi E. Intravitreal injection therapy in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51:110- 21. Epub 2012/04/21. doi: 10.1159/000336471 
000336471 [pii]. PubMed PMID: 22517209.  
16. Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011;22(6):517 -22. Epub 2011/09/08. doi: 
10.1097/ICU.0b013e32834bbd68. PubMed PMID: 21897242.  
17. Lobo AM, Sobrin L, Papaliodis GN. Drug delivery options for the treatment of ocular inflammation. Semin Ophthalmol. 2010;25(5 -6):283 -8. Epub 2010/11/26. doi: 
10.3109/08820538.2010.518522. PubMed PMID: 21091013.  
18. Sallam A, Comer RM, Chang JH, Grigg JR, Andrews R, McCluskey PJ, et al. S hort -term safety and 
efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol. 2008;126(2):200 -5. Epub 2008/02/13. doi: 10.1001/archophthalmol.2007.59 
126/2/200 [pii]. PubMed PMID: 18268210.  
19. Beer PM, Bakri  SJ, Singh RJ, Liu W, Peters GB, 3rd, Miller M. Intraocular concentration and 
pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681- 6. Epub 2003/04/12. doi: S0161- 6420(02)[ZIP_CODE] -3 [pii] 
10.1016/S0161 -6420(02)[ZIP_CODE]- 3. PubMed PMID: 12689886.  
20. Tranos P, Scott R, Zambarakji H, Zambarajki H, Ayliffe W, Pavesio C, et al. The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, 
controlled pi[INVESTIGATOR_799]. The British journal of ophthalmology. 2006;90(16723360):1107 -10. 
21. Becker MD, Harsch N, Zierhut M, Davis JL, Holz FG. [Therapeutic vitrectomy in uveitis: current 
status and recommendations]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologische n Gesellschaft. 2003;100(10):787- 95. Epub 2003/11/18. doi: 
10.1007/s00347 -003-0918- 8. PubMed PMID: 14618350.  
22. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525- 33. Epub 2008/09/03. doi: 10.1038/ncprheum0898 ncprheum0898 
[pii]. PubMed PMID: 18762788.  
23. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF -induced vascular leakage in a rabbit 
model of blood -retinal and blood -aqueous barrier breakdown. Exp Eye Res. 2005;80(2):249 -58. 
Epub 2005/01/27. doi: S0014- 4835(04)[ZIP_CODE]- 4 [pii] 10.1016/j.exer.2004.09.013. PubMed PMID: 
15670803.  
24. Vinores SA, Chan CC, Vinores MA, Matteson DM, Chen YS, Klein DA, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998;89(1 -2):43- 50. Epub 1998/09/03. PubMed PMID: 9726824.  
25. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis -associated cystoid macular edema. Am J Ophthalmol. 
2001;132(5):794- 6. Epub 2001/11/13. PubMed PMID: 11704050.  
26. Weiss K, Steinbrugger I, Weger M, Ardjomand N, Maier R, Wegscheider BJ, et al. Intravitreal 
VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal 
bevacizumab. Eye (Lond). 2009;23(9):1812- 8. Epub 2009/01/27. doi: 10.1038/eye.2008.388. 
PubMed PMID: 19169227.  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 38 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \[ADDRESS_824015] cytokine and chemokine 
profiles in the aqueous of patients with uveitis and cystoid macular edema. American journal of 
ophthalmology. 2006;142(16815285):192- 4. 
28. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271(2):736 -41. Epub 1996/01/12. PubMed 
PMID: 8557680.  
29. Jennings T, Rusin MM, Tessler HH, Cunha -Vaz JG. Posterior sub -Tenon's injections of 
corticosteroids in uveitis patients with c ystoid macular edema. Jpn J Ophthalmol. 
1988;32(4):385 -91. Epub 1988/01/01. PubMed PMID: 3236561.  
30. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;1 20(1):55 -64. Epub 1995/07/01. 
PubMed PMID: 7611330.  
31. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108(4) :765 -72. Epub 2001/04/12. PubMed PMID: 11297495.  
32. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol. 2004;138(2):289 -91. Epub 2004/08/04. doi: 10.1016/j.ajo.2004.02.053. PubMed 
PMID: 15289142.  
33. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916 e1- 7. Epub 2005/09/21. doi: 
10.1016/j.ophtha.2005.06.009. PubMed PMID: 16171868.  
34. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29(1):2 -6. Epub 
2001/03/29. PubMed PMID: 11272779.  
35. Sorensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand. 2005;83(1):67 -70. Epub 2005/02/18. 
doi: 10.1111/j.1600- 0420.2004.[ZIP_CODE].x. PubMed PMID: 15715560.  
36. Sallam A, Comer RM, Chang JH, Grigg JR, Andrews R, McCluskey PJ, et al. Short- term safety and 
efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Archives of ophthalmology. 2008;126(2):200- 5. Epub 2008/0 2/13. doi: 10.1001/archophthalmol.2007.59. 
PubMed PMID: 18268210.  
37. Hogewind BFT, Zijlstra C, Klevering BJ, Hoyng CB. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. European journ al of 
ophthalmology. 2008;18(18465727):429- 34. 
38. Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005;13(2- 3):205- 12. Epub 2005/07/16. doi: 10.1080/09273940590933511. PubMed PMID: 
16019680.  
39. Oueghlani E, Pavesio CE. Intravitreal triamcinolone injection for unresponsive cystoid macular oedema in probable Behcet's disease as an additional therapy. Klin Monbl Augenheilkd. 2008;225(5):497- 9. Epub 2008/05/06. doi: 10.1055/s -2008- 1027351. PubMed PMID: 18454410.  
40. Choudhry S, Ghosh S. Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema. Clin Experiment Ophthalmol. 2007;35(8):713 -8. Epub 
2007/11/14. doi: 10.1111/j.1442- 9071.2007.[ZIP_CODE].x. PubMed PMID: 17997773.  
41. Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek- Imhoff B, Heiligenhaus A. Intravitreal and 
orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. 
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 39 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 Ophthalmic research. 2009;42(2):81 -6. Epub 2009/05/30. doi: 10.1159/000220600. PubMed 
PMID: 19478546.  
42. Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub -
Tenon's corticosteroid therapy for cy stoid macular edema refractory to topi[INVESTIGATOR_5910]. 
Ophthalmology. 1997;104(12):2003- 8. Epub 1997/12/24. PubMed PMID: 9400758.  
43. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side -effects of 
injection of posterior s ub-Tenon triamcinolone versus orbital floor methylprednisolone in the 
management of posterior uveitis. Clin Experiment Ophthalmol. 2004;32(6):563 -8. Epub 
2004/12/04. doi: 10.1111/j.1442- 9071.2004.[ZIP_CODE].x. PubMed PMID: 15575824.  
44. Venkatesh P, Kumar CS, A bbas Z, Garg S. Comparison of the efficacy and safety of different 
methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16(5):217 -23. Epub 
2008/12/10. doi: 10.1080/09273940802209153 906501573 [pii]. PubMed PMID: 19065416.  
45. By[CONTACT_15502], Park YH. Complications and safety profile of posterior subtenon injection of 
triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;25(2):159 -62. Epub 2009/03/17. doi: 
10.1089/jop.2008.0087. PubMed PMID: 19284323; PubMed Central PMCID: PMC19284323.  
46. Leder HA, J abs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections 
for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(21652023):441- 8. 
47. Hirano Y, Ito T, Nozaki M, Yasukawa T, Sakurai E, Yoshida M, et al. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol. 2009;53(5):519 -22. Epub 2009/10/23. doi: 10.1007/s10384- 009-0692 -5. PubMed 
PMID: 19847609.  
48. Jonas JB, Degenring RF , Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after 
intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112(4):593 -8. Epub 
2005/04/06. doi: S0161- 6420(04)[ZIP_CODE] -7 [pii] 10.1016/j.ophtha.2004.10.042. PubMed PMID: 
[ZIP_CODE] 249.  
49. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740 -3. Epub 2004/11/09. doi: S0002-
9394(04)[ZIP_CODE]- 7 [pii] 10.1016/j.ajo.2004.06.067. PubMed PMID: 15531307.  
50. G illies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal 
injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336- 40. Epub 2004/03/10. doi: 10.1001/archopht.122.3.336 122/3/ 336 [pii]. 
PubMed PMID: 15006845.  
51. van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14(2):73 -85. 
Epub 2006/04/07. doi: 10.1080/09273940500545684. PubMed PMID: 16597536.  
52. Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani -Asenbauer T. Intravitreal 
triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol. 2009;37( 4):389- 96. Epub 2009/07/15. doi: 10.1111/j.1442-
9071.2009.[ZIP_CODE].x CEO2033 [pii]. PubMed PMID: 19594566.  
53. Gillies MC, Islam FM, Zhu M, Larsson J, Wong TY. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol. 2007;91(10):1323- 6. Epub 2007/04/05. doi: bjo.2006.113167 [pii] 10.1136/bjo.2006.113167. 
PubMed PMID: 17405800; PubMed Central PMCID: PMC2000996.  
54. Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD. Long -term inci dence and timing 
of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116(3):455- 60. Epub 2009/01/23. doi: 10.1016/j.ophtha.2008.10.002 S0161-
6420(08)[ZIP_CODE]- 1 [pii]. PubMed PMID: 19157561.  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 40 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 55. Das-Bhaumik RG,  Jones NP. Low -dose intraocular triamcinolone injection for intractable macular 
oedema and inflammation in patients with uveitis. Eye (Lond). 2006;20(8):934 -7. Epub 
2005/08/13. doi: 6702063 [pii] 10.1038/sj.eye.6702063. PubMed PMID: 16096656.  
56. Jonas JB,  Schlichtenbrede F. Visual acuity and intraocular pressure after high -dose intravitreal 
triamcinolone acetonide in selected ocular diseases. Eye (Lond). 2008;22(7):869 -73. Epub 
2007/02/17. doi: 10.1038/sj.eye.6702734. PubMed PMID: 17304257.  
57. Angunawela RI, Heatley CJ, Williamson TH, Spalton DJ, Graham EM, Antcliffe RJ, et al. 
Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm 
management and outcome. Acta Ophthalmol Scand. 2005;83(5):595 -9. Epub 2005/09/29. doi: 
AOS438 [pii] 10.1111/j.1600 -0420.2005.[ZIP_CODE].x. PubMed PMID: 16187999.  
58. Sallam A, Taylor SR, Habot -Wilner Z, Elgohary M, Do HH, McCluskey P, et al. Repeat intravitreal 
triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol. 2012;90( 4):e323 -5. Epub 2011/09/15. doi: 10.1111/j.1755- 3768.2011.[ZIP_CODE].x. PubMed PMID: 
21914149.  
59. Menezo V, Lau C, Comer M, Lightman S. Clinical outcome of chronic immunosuppression in 
patients with non -infectious uveitis. Clin Experiment Ophthalmol. 2005;33(1 ):16-21. Epub 
2005/01/27. doi: CEO904 [pii] 10.1111/j.1442- 9071.2005.[ZIP_CODE].x. PubMed PMID: 15670073.  
60. Habot -Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S. Intravitreal 
triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular 
edema. Eur J Ophthalmol. 2011;[ADDRESS_824016] 6:S56 -61. Epub 2011/01/01. doi: 
10.5301/EJO.2010.6062 FAF60F5D- AF35 -40A4 -8BCB- 3A28F23F419A [pii]. PubMed PMID: 
23264330.  
61. da Silva GR, da Silva Cunha A, Jr., Ayres E, Orefice RL. Effect of the  macromolecular architecture 
of biodegradable polyurethanes on the controlled delivery of ocular drugs. J Mater Sci Mater Med. 2009;20(2):481 -7. Epub 2008/10/15. doi: 10.1007/s10856- 008-3607 -y. PubMed PMID: 
18853235.  
62. Kuppermann BD, Blumenkranz MS, Hall er JA, Williams GA, Weinberg DV, Chou C, et al. 
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309 -17. Epub 
2007/03/14. doi: 125/3/309 [pii] 10.1001/archopht.125.3.309. PubMed PMID: 17353400.  
63. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, et al. Dexamethasone posterior -segment drug delivery system in the treatment of macular edema 
resulting from uveitis or Irvine -Gass syndrome. Am J Ophthalmol. 2009;147(6):1048 -54, 54 e1- 2. 
Epub 2009/03/10. doi: 10.1016/j.ajo.2008.12.033 S0002- 9394(09)[ZIP_CODE]- 6 [pii]. PubMed PMID: 
19268890.  
64. Herrero -Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained -release 
dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139 -46. Epub 
2011/03/09. doi: 10.2147/OPTH.S15783. PubMed PMID: 21383939; PubMed Central PMCID: PMC3045060.  
65. Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the trea tment of noninfectious 
uveitis. Clin Ophthalmol. 2011;5:1613 -21. Epub 2011/12/06. doi: 10.2147/OPTH.S17419 opth -5-
1613 [pii]. PubMed PMID: 22140307; PubMed Central PMCID: PMC3225458.  
66. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351- 66. Epub 2011/04/16. doi: 10.1007/s12325 -011-0019- z. 
PubMed PMID: 21494891.  
67. Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011;12(7):1127 -31. Epub 2011/0 4/05. doi: 10.1517/14656566.2011.571209. PubMed PMID: 
21457057.  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 41 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 68. Lowder C, Belfort R, Jr., Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. 
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545 -53. Epub 2011/01/12. doi: 10.1001/archophthalmol.2010.339 
archophthalmol.2010.339 [pii]. PubMed PMID: 21220619.  
69. Myung JS, Aaker GD, Kiss S. Treatment of noninfectious posterior uveitis with dexamethasone 
intravitreal implant. Clin Ophth almol. 2010;4:1423 -6. Epub 2010/12/29. doi: 
10.2147/OPTH.S15696. PubMed PMID: 21188153; PubMed Central PMCID: PMC3000767.  
70. Miserocchi E, Modorati G, Pastore MR, Bandello F. Dexamethasone intravitreal implant: an 
effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica. 2012;228(4):229- 33. Epub 2012/10/06. doi: 10.1159/000343060 000343060 [pii]. PubMed 
PMID: 23038070.  
71. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, et al. Repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmologica. 
2013;229(1):21- 5. Epub 2012/09/26. doi: 10.1159/000342160 000342160 [pii]. PubMed PMID: 
23006995.  
72. Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A, et al. Phar macokinetic -
pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45(10):3435 -
41. Epub 2004/09/29. doi: 10.1167/iovs.03 -1110 45/10/3435 [pii].  PubMed PMID: 15452046.  
73. Nussenblatt RB, Kaufman SC, Palestine AG, Davis MD, Ferris FL, 3rd. Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. Ophthalmology. 1987;94(9):1134 -9. Epub 1987/09/01. PubMed PMID: 368423 1. 
74. Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, et al. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by [CONTACT_7349]. Am J Ophthalmol. 2011;152(6):1044 -52.e5. Epub 2011/ 08/25. doi: 
10.1016/j.ajo.2011.05.028. PubMed PMID: 21861971; PubMed Central PMCID: PMCPmc3223264.  
75. Ferris FL, 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91- 6. Epub 1982/07/01. PubMed PMID: 7091289.  
76. Kimura SJ, Thygeson P, Hogan MJ. Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis. Am J Ophthalmol. 1959;47(5 Pt 2):171 -6. Epub 1959/05/01. 
PubMed PMID: 13649856.  
77. Nussenblatt R, Whitcup,  SM, Palestine, AG. Uveitis: Fundamentals and Clinical Practice. [ADDRESS_824017]. 
Louis: Mosby; 1996.  
78. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory 
activity in intermediate and posterior uveitis. Ophthalmology. 1985 ;92(4):467- 71. Epub 
1985/04/01. PubMed PMID: 4000641.  
79. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting 
clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509 -16. 
Epub 200 5/10/01. PubMed PMID: 16196117.  
80. The age- related eye disease study (AREDS) system for classifying cataracts from photographs: 
AREDS report no. 4. Am J Ophthalmol. 2001;131(2):167 -75. Epub 2001/03/03. PubMed PMID: 
11228291; PubMed Central PMCID: PMCPmc2032014.  
81. Lehpamer B, Moshier E, Pahk P, Goldberg N, Ackert J, Godbold J, et al. Epi[INVESTIGATOR_619702]: effect on vision and response to therapy. Am J Ophthalmol. 
2014;157(5):1048- 55. Epub 2014/02/04. doi: 10.1016/j.ajo.2014.01.020. PubMed PMID: 
24487049; PubMed Central PMCID: PMCPmc4060278.  
82. Ozurdex (package insert). Allergan, Inc. Irvine, CA [ZIP_CODE]: 2013.  
POINT PROTOCOL VERSI ON 2.1 (16 FEB  2017)  References  ‚îÇ 42 
 
P:\Doc\MUST \POINT \protocol \17 02 16_2.1 \17 02 16 POINT protocol 2 1.docx  
 83. Triesence (package insert). Alcon. Fort Worth, TX [ZIP_CODE]: 2008.  
84. LUCENTIS (ranibizumab injection) (Package Insert). Gen entech Inc. South San Francisco, CA 
[ZIP_CODE]: February 2013.  
85. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after 
anti-vascular endothelial growth factor therapy in Medicare patients with age -related macular 
degeneration. Am J Ophthalmol. 2011;152(2):266 -72. Epub 2011/06/15. doi: 
10.1016/j.ajo.2011.01.053. PubMed PMID: 21664593; PubMed Central PMCID: PMCPMC3143287.  
86. Manatunga AK, Chen S. Sample size estimation for survival outcomes in cluster- randomized 
studies with  small cluster sizes. Biometrics. 2000;56(2):616 -21. Epub 2000/07/06. PubMed 
PMID: 10877325.  
87. Ferris FL, 3rd, Miller KM, Glassman AR, Beck RW. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology. 2010;117(8):1512- 6. Epub 2010/04/07. doi: 10.1016/j.ophtha.2009.12.014. 
PubMed PMID: 20363505; PubMed Central PMCID: PMCPmc2916055.  
88. Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, et al. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with 
diabetic macular edema. Ophthalmology. 2007;114(8):1520 -5. Epub 2007/03/14. doi: 
10.1016/j.ophtha.2006.10.055. PubMed PMID: 17353052; PubMed Central PMCID: PMCPmc2253719.  
89. Lehpamer B, Moshier E, Goldberg N, Ackert J, Godbold J, Jabs DA. Subretinal fluid in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol. 2013;155(1):143 -9. 
Epub 2012/10/02. doi: 10.1016/j.ajo.2012.06.028. PubMed PMID: 23022159.  
90. Diggle P HP, Liang K -Y, Zeger S. Analysis of Longitudinal Data. [LOCATION_001]: Oxford University Press 
Inc.; 2002.  
91. Gutierrez R. Parametric frailty and shared frailty survival models. The Stata Journal. 2002;2(1):22- 44. 
92. Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, et al. Methods to assess population effectiveness of therapi[INVESTIGATOR_619703]. Am J Epi[INVESTIGATOR_5541]. 2001;154(7):675 -81. Epub 2001/10/03. PubMed PMID: 11581102.  
93. Keene O N, Jones MR, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic 
obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat. 2007;6(2):89 -97. 
Epub 2007/01/19. doi: 10.1002/pst.250. PubMed PMID: 17230434.  
94. Wang R, Lag akos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of 
subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189 -94. Epub 2007/11/23. doi: 
10.1056/NEJMsr077003. PubMed PMID: 18032770.  
95. Daniels MJ HJ. Missing Data in Lon gitudinal Studies: Strategies for Bayesian Modeling and 
Sensitivity Analysis. Boca Raton: Chapman & Hall/CRC; 2008.  
96. Little RJA RD. Statistical Analysis with Missing Data . 2nd ed. [LOCATION_001]: John Wiley & Sons; 2002.  
 